Stay updated on Pembrolizumab in Untreated B-Cell NHL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page
- Check7 days agoChange DetectedThe study page for NCT03498612 now renders a 403 Forbidden page, replacing the usual study details. Users attempting to view the record will see the 403 page instead of trial content.SummaryDifference19%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe revision indicator on the page was updated from v3.6.5 to v3.6.6, reflecting a newer site version.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page changed from an error page to a full study record for NCT03498612, adding the study overview, design details, eligibility criteria, locations, outcomes, and links to related documents such as the Study Protocol and Statistical Analysis Plan.SummaryDifference52%

- Check49 days agoChange DetectedRevision: v3.6.5 replaces v3.6.4 on the page. This appears to be a small site maintenance update rather than a change to the study information.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page now shows a revised tag, updating from v3.6.3 to v3.6.4, indicating a minor site update. This does not alter study details or how the page operates.SummaryDifference0.1%

- Check84 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, representing a small update to the page metadata.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Untreated B-Cell NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page.